CHF 1.6m · Other round · Healthtech · Zurich, Switzerland
Zurich-based KOVE Medical has raised CHF 1.6m in financing from a syndicate of angel investors to move its amniotic-sac closure device from preclinical development towards a First-in-Human study. EU-Startups reported the round on 31 August; the University of Zurich later confirmed the amount and clinical milestone.
KOVE was founded in 2020 by Yannick Devaud and Kurt Ruffieux as a spin-off from the University of Zurich and University Hospital Zurich. Its technology grew from doctoral research involving EPFL and the Zurich hospital.
Closing the access point after fetal surgery
Fetoscopic surgery lets clinicians treat conditions including spina bifida, twin-to-twin transfusion syndrome and congenital diaphragmatic hernia before birth. The procedure requires instruments to pass through the uterine wall and amniotic sac, leaving a defect that can leak fluid and contribute to premature membrane rupture and preterm birth. KOVE says its implant is delivered through the existing fetoscopic port and closes the membrane from inside the amniotic cavity, without another puncture.
That workflow fit is commercially important. A closure device that uses the same access route and adds less than five minutes to the procedure could be easier for fetal-surgery centres to introduce than a system requiring separate instruments or a new surgical step. The proposition still depends on clinical evidence: compatibility and speed can lower adoption friction, but surgeons and regulators will need data showing that the device can be placed consistently and improves outcomes without creating new risks.
The round funds a clinical transition, not market launch
The financing is intended to take KOVE towards its first use in people, rather than directly into commercial deployment. That is a defined value step for an implantable device: the company must turn preclinical work into an approved study, demonstrate manufacturing consistency and produce initial human safety and performance evidence.
KOVE has already described pre-series production and process-validation work with specialist manufacturing partners in France and Switzerland. Those preparations matter because the device combines a delicate clinical application with a supply chain that must reproduce high-precision components, assembly and packaging. The new capital therefore has to advance two tracks together: clinical readiness and a controlled manufacturing process capable of supplying the study. A successful first-in-human milestone would not complete development, but it would give later investors and clinical partners evidence that the closure concept can move beyond the laboratory.
Sources checked:
EU-Startups · University of Zurich Innovation Hub · KOVE Medical technology · KOVE Medical company · KOVE Medical LinkedIn · Tech.eu Funding Explorer
The display date uses the dated 31 August 2026 report; the University of Zurich confirmed the financing on 3 September.
